Marloes Nies1, Mariëlle S Klein Hesselink1, Gea A Huizinga2,3, Esther Sulkers2, Adrienne H Brouwers4, Johannes G M Burgerhof5, Eveline W C M van Dam6, Bas Havekes7, Marry M van den Heuvel-Eibrink8, Eleonora P M Corssmit9, Leontien C M Kremer10, Romana T Netea-Maier11, Heleen J H van der Pal10,12, Robin P Peeters13, John T M Plukker14, Cécile M Ronckers10, Hanneke M van Santen15, Wim J E Tissing3, Thera P Links1, Gianni Bocca16. 1. Department of Endocrinology. 2. Wenkebach Institute, School of Nursing and Health, Departments of. 3. Pediatric Oncology and. 4. Nuclear Medicine and. 5. Molecular Imaging, Epidemiology, and. 6. Department of Internal Medicine, VU University Medical Center, 1007 MB Amsterdam, The Netherlands. 7. Division of Endocrinology, Department of Internal Medicine, Maastricht University Medical Center, 6202 AZ Maastricht, The Netherlands. 8. Department of Pediatric Oncology, Sophia Children's Hospital, Erasmus Medical Center, 3000 CB Rotterdam, The Netherlands. 9. Division of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands. 10. Department of Pediatric Oncology, Emma Children's Hospital, and. 11. Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands. 12. Department of Medical Oncology, Academic Medical Center, 1100 DD Amsterdam, The Netherlands. 13. Department of Internal Medicine and Rotterdam Thyroid Center, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands. 14. Surgical Oncology. 15. Department of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands. 16. Pediatric Endocrinology, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands.
Abstract
Context: Little is known about long-term quality of life (QoL) of survivors of pediatric differentiated thyroid carcinoma. Therefore, this study aimed to evaluate generic health-related QoL (HRQoL), fatigue, anxiety, and depression in these survivors compared with matched controls, and to evaluate thyroid cancer-specific HRQoL in survivors only. Design: Survivors diagnosed between 1970 and 2013 at age ≤18 years, were included. Exclusion criteria were a follow-up <5 years, attained age <18 years, or diagnosis of DTC as a second malignant neoplasm (SMN). Controls were matched by age, sex, and socioeconomic status. Survivors and controls were asked to complete 3 questionnaires [Short-Form 36 (HRQoL), Multidimensional Fatigue Inventory 20 (fatigue), and Hospital Anxiety and Depression Scale (anxiety/depression)]. Survivors completed a thyroid cancer-specific HRQoL questionnaire. Results: Sixty-seven survivors and 56 controls. Median age of survivors at evaluation was 34.2 years (range, 18.8 to 61.7). Median follow-up was 17.8 years (range, 5.0 to 44.7). On most QoL subscales, scores of survivors and controls did not differ significantly. However, survivors had more physical problems (P = 0.031), role limitations due to physical problems (P = 0.021), and mental fatigue (P = 0.016) than controls. Some thyroid cancer-specific complaints (e.g., sensory complaints and chilliness) were present in survivors. Unemployment and more extensive disease or treatment characteristics were most frequently associated with worse QoL. Conclusions: Overall, long-term QoL in survivors of pediatric DTC was normal. Survivors experienced mild impairment of QoL in some domains (physical problems, mental fatigue, and various thyroid cancer-specific complaints). Factors possibly affecting QoL need further exploration.
Context: Little is known about long-term quality of life (QoL) of survivors of pediatric differentiated thyroid carcinoma. Therefore, this study aimed to evaluate generic health-related QoL (HRQoL), fatigue, anxiety, and depression in these survivors compared with matched controls, and to evaluate thyroid cancer-specific HRQoL in survivors only. Design: Survivors diagnosed between 1970 and 2013 at age ≤18 years, were included. Exclusion criteria were a follow-up <5 years, attained age <18 years, or diagnosis of DTC as a second malignant neoplasm (SMN). Controls were matched by age, sex, and socioeconomic status. Survivors and controls were asked to complete 3 questionnaires [Short-Form 36 (HRQoL), Multidimensional Fatigue Inventory 20 (fatigue), and Hospital Anxiety and Depression Scale (anxiety/depression)]. Survivors completed a thyroid cancer-specific HRQoL questionnaire. Results: Sixty-seven survivors and 56 controls. Median age of survivors at evaluation was 34.2 years (range, 18.8 to 61.7). Median follow-up was 17.8 years (range, 5.0 to 44.7). On most QoL subscales, scores of survivors and controls did not differ significantly. However, survivors had more physical problems (P = 0.031), role limitations due to physical problems (P = 0.021), and mental fatigue (P = 0.016) than controls. Some thyroid cancer-specific complaints (e.g., sensory complaints and chilliness) were present in survivors. Unemployment and more extensive disease or treatment characteristics were most frequently associated with worse QoL. Conclusions: Overall, long-term QoL in survivors of pediatric DTC was normal. Survivors experienced mild impairment of QoL in some domains (physical problems, mental fatigue, and various thyroid cancer-specific complaints). Factors possibly affecting QoL need further exploration.
Authors: Marloes Nies; Bernadette L Dekker; Esther Sulkers; Gea A Huizinga; Mariëlle S Klein Hesselink; Heleen Maurice-Stam; Martha A Grootenhuis; Adrienne H Brouwers; Johannes G M Burgerhof; Eveline W C M van Dam; Bas Havekes; Marry M van den Heuvel-Eibrink; Eleonora P M Corssmit; Leontien C M Kremer; Romana T Netea-Maier; Heleen J H van der Pal; Robin P Peeters; John T M Plukker; Cécile M Ronckers; Hanneke M van Santen; Anouk N A van der Horst-Schrivers; Wim J E Tissing; Gianni Bocca; Thera P Links Journal: Eur J Endocrinol Date: 2017-12-18 Impact factor: 6.664
Authors: L M E van Erp; H Maurice-Stam; L C M Kremer; W J E Tissing; H J H van der Pal; A C H de Vries; M M van den Heuvel-Eibrink; B A B Versluys; M van der Heiden-van der Loo; G A Huizinga; M A Grootenhuis Journal: Support Care Cancer Date: 2021-02-01 Impact factor: 3.359
Authors: Marloes van Gorp; Loes M E van Erp; Anne Maas; Leontien C M Kremer; Eline van Dulmen-den Broeder; Wim J E Tissing; Jacqueline J Loonen; Helena J H van der Pal; Andrica C H de Vries; Marry M van den Heuvel-Eibrink; Cécile M Ronckers; Dorine Bresters; Marloes Louwerens; Margriet van der Heiden-van der Loo; Gea A Huizinga; Heleen Maurice-Stam; Martha A Grootenhuis Journal: Cancer Date: 2021-11-02 Impact factor: 6.921
Authors: Salome Christen; Katharina Roser; Renée L Mulder; Anica Ilic; Hanne C Lie; Jacqueline J Loonen; Anneli V Mellblom; Leontien C M Kremer; Melissa M Hudson; Louis S Constine; Roderick Skinner; Katrin Scheinemann; Jordan Gilleland Marchak; Gisela Michel Journal: J Cancer Surviv Date: 2020-08-25 Impact factor: 4.442
Authors: Susan C Pitt; Megan C Saucke; Elizabeth M Wendt; David F Schneider; Jason Orne; Cameron L Macdonald; Nadine P Connor; Rebecca S Sippel Journal: Thyroid Date: 2020-11-04 Impact factor: 6.568